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Summary. Higher self-efficacy in chronic disease
patients is associated with higher development of
self-management skills and increased quality-of-life.
Quantification and monitoring of self-efficacy is
therefore of importance. Self-efficacy in haemophilia
patients has received little attention due to lack of
standardized scales. To validate the novel Haemo-
philia-specific Self-Efficacy Scale (HSES) in haemophilia
patients on prophylactic home treatment, haemophilia
patients aged 1–18 years on prophylactic treatment
≥1 year were included from three Dutch Haemophilia
Treatment Centres. The HSES consists of 12 items,
relating to perceptions of the ability to function on a
day-to-day basis with regard to patient’s disease. Retest
was performed in a subsample. Validity was proven by
the General Self-Efficacy Scale and by the health-related
quality-of-life assessment tool Haemo-QoL. Data were
analysed from 53 children (response 75%), with a
mean age of 9.8 years (SD 4.0). Mean total scale score
of HSES was 55.5 (SD 4.7; range 38–60), with a
ceiling effect of 17%. The HSES showed adequate
internal consistency (Cronbach’s alpha 0.72) and
good test–retest reliability (Intra-Class-Correlation
coefficient 0.75; P < 0.01; n = 37). The convergent
validity was adequate as haemophilia-specific self-
efficacy correlated significantly with general self-
efficacy (r = 0.38; P < 0.01). High HSES scores
correlated significantly with quality-of-life as
measured by the Haemo-QoL (r = 0.42; P ≤ 0.01).
The novel HSES is a reliable and valid tool to assess
self-efficacy in paediatric haemophilia patients on
prophylactic home treatment. High self-efficacy
correlated with higher quality-of-life, further
underlining the importance to standardly assess,
monitor and improve self-efficacy.
Keywords: children, haemophilia, health status, instru-
ment development, self-efficacy, validity
Introduction
In haemophilia, as in other chronic diseases, self-man-
agement skills of patients and caretakers are of rele-
vance for treatment adherence, prognosis of disease and
quality-of-life [1]. Prophylactic replacement therapy
with clotting factor concentrate in the home setting
requires a high ability of self-management as organiza-
tion of care is complex (Lock J, Raat H, Duncan N,
Shapiro A, Beijlevelt M, Peters M, Tamminga RYJ,
Leebeek FWG, Moll HA, Cnossen MH, Submitted;
[2]). It includes insight on the necessity and dosing of
clotting factor concentrate, taking prior prophylactic
doses into account. Also practical and logistic capacities
are of significance with regard to clotting factor concen-
trate infusion, stock and timely communication with
the Haemophilia Treatment Centre (HTC).
Bandura developed the concept of ‘self-efficacy’. This
term describes the actual confidence an individual pos-
sesses with regard to specific actions necessary to
achieve certain results [3]. It summarizes the integration
of a motivated attitude towards a disease and its treat-
ment, a capacity towards adequate judgment with
regard to therapeutic interventions and demonstration
of adherence to prescribed therapy [4]. Patients with
low self-efficacy are less likely to persevere in a specific
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task when impediments arise, obliterating usual pro-
ceedings. Those with high self-efficacy will deploy all
abilities to master obstacles. In clinical practice, self-
efficacy is considered an antecedent for modification of
behaviour [5,6]. Furthermore, development of disease-
specific self-efficacy questionnaires is required to take
disease-specific aspects into account not dealt with by
the current validated general questionnaire.
In various chronic diseases high levels of self-effi-
cacy are associated with higher quality-of-life and less
clinical and psychological symptoms [5,7–9]. In addi-
tion, Richardson et al. reported that patients with a
wide range of chronic diseases value self-efficacy
highly, and are willing to trade reductions in health-
related quality-of-life for improvements in their self-
efficacy [10]. In haemophilia, a number of studies
have evaluated general self-efficacy and possible train-
ing modules, but few have looked at disease-specific
self-efficacy.
Kang et al. proved that a self-help program for
mothers of children with haemophilia significantly
improved knowledge, self-efficacy and quality-of-life
[11,12]. Mulders et al. reported that an educational
e-learning program in patients on prophylactic home
treatment significantly improved general knowledge of
treatment [13]. However, in this cohort, self-efficacy
scores were relatively high at initiation and did not
increase after intervention. Conflicting results were
found by Barlow et al. and Buxbaum et al., as the first
documented high levels of self-efficacy in haemo-
philia patients, indicating a well-developed confidence
with regard to disease management, whereas the lat-
ter found lower self-efficacy scores in haemophilia
patients than in healthy controls [14,15]. All studies
were performed using a general self-efficacy scale or a
non-validated Haemophilia-specific Self-Efficacy Scale
(HSES) as there was no validated HSES available. To
adequately quantify and monitor self-efficacy and to
identify subgroups at risk of higher morbidity and
decreased quality-of-life, the HSES was recently devel-
oped and validated. This study aims to describe the
psychometric properties of this novel instrument and
the association between HSES and quality-of-life.
Patients and methods
Patients
Data for this cross-sectional, multicentre study were
collected as part of a larger prospective study on the
efficacy of home-treatment intervention by a trained
haemophilia nurse (Netherlands Trial Register: 2543).
Between June 2010 and December 2011, we enrolled
children aged 1–18 years with haemophilia A or B on
prophylaxis and home treatment for at least 1 year,
from three HTC’s in the Netherlands (Erasmus Medi-
cal Centre – Sophia Children’s Hospital, Rotterdam;
Academic Medical Centre – Emma Children’s Hospital,
Amsterdam; University Medical Centre Groningen).
Patients and parents were required to speak and under-
stand Dutch sufficiently. Patients with inhibitors against
FVIII or FIX were excluded. One caregiver, primarily
involved in the child’s daily haemophilia treatment, and
adolescents aged 10–18 years were asked to complete
the questionnaire. To evaluate test–retest reliability of
HSES, the questionnaire was sent two weeks after
administration of the first questionnaire to consenting
participants. Participants not returning the question-
naires within 2 weeks received reminders and were con-
sidered lost to follow-up after two unreturned
messages. The Medical Ethical Committee granted per-
mission to perform the study and written informed con-
sent was obtained [MEC2010097].
Data collection
Socio-demographic data, including parental level of
education, employment status and family structure
were provided. For level of education the International
Standard Classification of Education (ISCED) division
into low, medium and high educational levels was
applied [16]. Low is equivalent to ISCED 0–2, i.e.
‘less than upper secondary level’; medium to ISCED
3–4, i.e. ‘upper secondary level’ and high to ISCED
5–6, meaning tertiary level, or minimally 2 years of
education after upper secondary level. Haemophilia
diagnosis, treatment and clotting factor consumption
were extracted from medical files.
Self-efficacy
Haemophilia-specific Self-Efficacy Scale
To specify disease-specific self-efficacy qualities, a
novel scale was developed and validated, specifically
for haemophilia patients. The HSES was composed by
a team of haemophilia professionals and psychologists
with items from the validated Sickle Cell Self-Efficacy
Scale [7,17], from the Pain Self-Efficacy Questionnaire
[18] and from the validated General Self-Efficacy Scale
[19,20]. The first two questionnaires were used as they
specifically encompass disease aspects such as periodic
immobilization and pain. The novel HSES consists of
12 items focusing on an individual’s perceptions of
haemophilia disease symptoms and the patient’s abili-
ties to cope with or reduce these symptoms. In our
view, all aspects of treatment are incorporated: treat-
ment efficacy, quality-of-life, infusion technique, state
of mind in case of a bleed, pain modification, confi-
dence, modification of prophylactic regimen, continua-
tion of daily activities, other therapeutic interventions
besides clotting factor treatment, belief in leading of a
normal life, communication and attainment of per-
sonal goals. Items are scored ranging from ‘I totally
Haemophilia (2014), 20, e267--e274 © 2014 John Wiley & Sons Ltd
e268 J. LOCK et al.
disagree’ to ‘I totally agree’ (see figure). On a five-
point Likert-scale, the lowest score was given one
point and the highest score five points. An unweighted
sum score was calculated by adding the 12 item
scores, with higher scores indicating greater self-effi-
cacy (range: 12–60).
General Self-Efficacy Scale (GSES)
To assess the convergent validity of the HSES, we used
the validated General Self-Efficacy Scale (GSES)
[19,20]. The GSES consists of 10 items on a four-point
Likert-scale, ranging from ‘I totally disagree’ to ‘I
totally agree’, with sum scores ranging from 10 to 40.
Higher scores also indicate greater general self-efficacy.
Although self-efficacy is considered to be task-specific,
we assumed the concepts of general self-efficacy and
haemophilia-specific self-efficacy to be related, which
is supported by literature in other diseases, when
assessing self-efficacy [21].
Haemo-QoL
The disease-specific quality-of-life instrument Haemo-
QoL was used to assess the divergent construct valid-
ity. This is a self-report measure for children with
haemophilia and their parents, consisting of 21–77
items which cover 9–11 domains depending on the
age group of the patient. Higher scores indicate lower
disease-specific quality-of-life [22].
VERITAS-Pro
To quantify treatment adherence in children on
prophylaxis, we used the Validated Haemophilia Regi-
men Treatment Adherence Scale–Prophylaxis (VERI-
TAS-Pro) (Lock J, Raat H, Duncan N, Shapiro A,
Beijlevelt M, Peters M, Tamminga RYJ, Leebeek FWG,
Moll HA, Cnossen MH, Submitted; [2]). This instru-
ment contains six subscales (‘Time’, ‘Dose’, ‘Plan’,
‘Remember’, ‘Skip’, ‘Communicate’), each represented
by four questions concerning a specific domain of hae-
mophilia patient care. Cumulative score of all subscales
ranges from 24 to 120 and cumulative scores per sub-
scale range from 4 to 20. Lower scores reflect higher
adherence.
Data analysis
Psychometric properties of HSES
The following psychometric properties of the HSES
were evaluated as follows: feasibility, reliability and
validity (convergent and divergent validity). Feasibility
was expressed as response rate. Scale scores were
described in terms of scale mean, SD, range, floor and
ceiling effects and percentiles.
The total scale internal consistency reliability was
assessed using Cronbach’s alpha. Amidst varying
standards in the literature, we considered 0.70 to be
an acceptable alpha coefficient [23].
The test–retest reliability was assessed by the Intra-
Class-Correlation Coefficients (ICC). The agreement
between the perceived haemophilia-specific self-effi-
cacy of parents and adolescents was also assessed by
the ICC.
Validity was assessed by comparing HSES outcomes
with the validated GSES and the Haemo-QoL. It was
hypothesized that a low HSES outcome should correlate
with low self-efficacy outcomes on the GSES and a low
quality-of-life (i.e. higher score) by Haemo-QoL. As
data were not normally distributed correlations in over-
all median sum scores were calculated and tested with
Spearman’s correlation coefficient. Low haemophilia-
specific self-efficacy was defined as the lowest quartile
of HSES scores, while high haemophilia-specific self-
efficacy was defined as the highest quartile of HSES
scores as data were not distributed normally.
Subgroup analyses were assessed by comparing
HSES outcomes with age, duration of prophylactic
home treatment, number of siblings, level of educa-
tion, marital status and family composition. We com-
pared the patient group with the lowest quartile of
HSES scores with the patient group with the highest
quartile of HSES scores. Due to non-parametrical
data, the continuous outcomes were assessed using the
Mann–Whitney U-test and categorical data were anal-
ysed by Chi-square test or the Fisher’s exact test in
case of low patient counts per subgroup.
Data were analysed separately for parent-reported
and adolescent-reported scales, except for the inter-
rater agreement analysis which compared adolescent-
reported with parent-reported scales.
We considered P-values <0.05 as statistically signifi-
cant; all tests were two-sided. All analyses were
performed using SPSS 20.0 for Windows.
Results
Participants
A total of 71 patients of which 40 adolescents
(10–18 years) were invited for study participation.
Eighteen parents of children, including parents of 12
adolescents declined or did not fill out the question-
naire. Reasons for non-participation included time bur-
den and logistical reasons. Fifty-three parents of both
young children and adolescents (parent-reported ques-
tionnaires; response 75%) and 28 adolescents (adoles-
cent-reported questionnaires; response 70%) were
participated. Table 1 describes the baseline characteris-
tics of all participants.
All 53 children were male with a mean age of
9.8 years (SD 4.0), 81% were diagnosed with
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haemophilia A, 89% had severe haemophilia. Of the
53 children, 28 were adolescents. The mean age of
this subgroup was 13.6 (SD 2.5). Mean duration of
prophylactic treatment was 7.1 years (SD 3.6), with a
median time span between prophylaxis initiation and
start of the home treatment of 0.5 years. Of the 53
parents, the majority was female (88%), 8% were
educated at a low level, 20% were single parents and
30% had two children or more.
Psychometric properties of the HSES
Table 2 displays the total scale scores. Mean total
scale scores were relatively high (55.5 for the
parent-report and 55.7 for the adolescent-report) as
were the median scores (57.0 for both the parent- and
the adolescent-report). Floor effects were absent. Ceil-
ing effects were observed in 17% of the parents and
in 29% of the adolescents.
The Cronbach’s alpha of the total scale was
a = 0.72 for the parent-report and a = 0.86 for the
adolescent-report, indicating an adequate internal
consistency (Table 2).
The test–retest reliability showed promising results,
with a ICC of 0.75 (95%CI 0.56:0.86; P < 0.01;
n = 37) for the parent-report and 0.67 (95%CI
0.29:0.87; P < 0.01; n = 17) for the adolescent-report.
For the parent-report there was no significant differ-
ence between the test (mean 55.70; SD 4.16) and the
retest (mean 55.88; SD 4.87; P = 0.34); also the ado-
lescent-report showed identical results (test mean
55.88; SD 4.87; retest mean 55.18; SD 3.89;
P = 0.37). The agreement between the perceived hae-
mophilia-specific self-efficacy of parents and adoles-
cents was however not significant (ICC 0.05; 95%CI
0.43:0.35; P = 0.59).
Significant Spearman’s correlations were observed
with the General Self-Efficacy Scale (parent-report:
r = 0.43; P < 0.05; adolescent-report: r = 0.81;
P < 0.01). For the quality-of-life determined by the
Haemo-QoL, the correlation of the total score was
only significant for the parent-report of the HSES
(r = 0.45; P < 0.01) and not significant for the ado-
lescent-report HSES (r = 0.02; P = 0.92). Parents with
a higher perceived self-efficacy (HSES) reported signifi-
cantly less adherence with regard to subscales ‘Plan’,
‘Remember’ and ‘Communication’ on the VERITAS-
Pro scale when compared with parents with a lower
perceived self-efficacy (respectively r = 0.28;
r = 0.29; r = 0.37; P < 0.05). No other correlations
were seen between the HSES (parent-report), the
HSES (adolescent-report) and other VERITAS-Pro
(sub)scales (Table 3).
Parents with HSES scores in the lowest quartile
reported significantly lower median scores on the: GSES
(P < 0.01); the Haemo-QoL (sub)scales ‘Total score’
(P < 0.01), ‘Feeling’ (P = 0.02), ‘View’ (P = 0.01),
‘Others’ (P = 0.03), and ‘Sport’ (P < 0.01); and on the
VERITAS-Pro subscales ‘Remember’ (P = 0.05), ‘Skip’
(P < 0.01) and ‘Communicate’ (P = 0.01), compared to
parents with HSES scores in the highest quartile
(Table 4). Adolescents with HSES scores in the lowest
quartile reported significantly lower median scores on
Table 1. Characteristics of the 53 participants at the time of study enrol-
ment.
Characteristic N (%)
Patient characteristics
Age patients (years), mean (SD) 9.8 (4.0)
Sex patients, male 53 (100)
Diagnosis
Haemophilia A 43 (81)
Haemophilia B 10 (19)
Severity of haemophilia
Severe (<1%) 47 (89)
Moderate (1–5%) 5 (9)
Mild (6–40%)* 1 (2)
Duration of prophylactic treatment (years), mean (SD) 7.1 (3.6)
Parent characteristics
Age parents (years), mean (SD) 39.8 (7.0)
Level of education†,‡
Low level of education 4 (8)
Medium level of education 33 (66)
High level of education 13 (26)
Marital status†
Married/registered partnership 11 (22)
Unmarried 30 (59)
Widow/widower 2 (4)
Divorced 8 (16)
Family composition†
Living with partner and child(ren) 40 (78)
Single with child(ren) 10 (20)
Other 1 (2)
Individual completing scale†
Mother/female guardian 45 (88)
Father/male guardian 6 (12)
Adolescent 28 (53)
*On prophylactic treatment due to bleeding tendency due to concomitant
von Willebrand disease.
†Of two participants no information is available on marital status, family
composition and whom filled out the questionnaire. Of three participants
no information is available on level of education.
‡The usual ISCED division into Low, Medium and High is adopted here,
as in the Eurostat Labour Force Survey. Low is equivalent to ISCED 0–2,
i.e. ‘less than upper secondary level of education’. Medium is given by IS-
CED 3–4, i.e. upper secondary level. High is ISCED 5–6, meaning tertiary
level, or two more years of education after upper secondary level.
Table 2. Score distribution and internal consistency reliability of the Haemophilia-specific Self-Efficacy Scale (HSES).
Scale scores
Internal consistency reliability
Mean (SD) Range Median [IQR] Ceiling effect (%)* Floor effect (%)† Cronbach’s alpha
Parent-report (n = 53) 55.45 (4.27) 45–60 57 [54–59] 17 0 0.72
Adolescent-report (n = 28) 55.68 (5.41) 38–60 57 [54–59] 29 0 0.86
*Ceiling effect; percentage of respondents with best possible score.
†Floor effect; percentage of respondents with worst possible score.
Haemophilia (2014), 20, e267--e274 © 2014 John Wiley & Sons Ltd
e270 J. LOCK et al.
the: GSES (P < 0.01); the Haemo-QoL subscales ‘Oth-
ers’ (P = 0.04) and ‘Treatment’ (P = 0.02), compared
to adolescents with HSES scores in the highest quartile
(Table 4).
Perceived disease-specific self-efficacy was not asso-
ciated with age, duration of prophylactic treatment,
level of education, number of siblings, marital status
or with family composition. Neither in parents nor in
adolescents (data not shown).
Discussion
The novel HSES is a feasible and reliable instrument
to evaluate self-efficacy in Dutch paediatric patients
with haemophilia on prophylactic home treatment. As
timely communication and intervention is obligatory
to modify prognosis in a disease with periodic epi-
sodes of pain and immobilization, we believe regular
evaluation of self-efficacy is essential. In our study,
HSES showed satisfactory psychometric properties
and was able to discriminate between high and low
self-efficacy. High HSES scores correlated significantly
with quality-of-life measured by the Haemo-QoL. Fur-
ther evaluation in other populations with regard to
age and cultural background is necessary to broaden
application possibilities of this valuable tool. Differen-
tiation of subgroups within the haemophilia patient
population with regard to self-efficacy is of paramount
importance to identify potential high-risk patients
with an increased risk of morbidity and decreased
quality-of-life [24,25]. Subsequently, patients may
undergo interventions aiming to increase self-efficacy,
ultimately leading to cost-reduction of treatment in
this era of rising health care costs.
Strengths of the HSES are diverse. Firstly, the 12
items chosen cover all aspects of haemophilia care in
which self-efficacy plays a role and follow the defini-
tion of self-efficacy as described by Bandura in 1977
[3]. Secondly, general self-efficacy and disease-specific
self-efficacy correlated significantly as did a higher
self-efficacy with a higher quality-of-life as evaluated
by HaemoQoL, a validated and widely used tool to
analyse quality-of-life in children and adolescents with
haemophilia. Furthermore, a high response rate was
reached among the study population, leading to reli-
ability of conclusions. Fourthly, as the HSES is an eas-
ily applied tool, it will allow monitoring of
interventions aimed to improve haemophilia-specific
self-efficacy. Finally, HSES is another example of a
combination of qualitative research and quantitative
survey techniques, such as seen in the development of
the VERITAS-Pro by Duncan et al. [2]. In our opin-
ion, this approach leads to richer, more valid and
more reliable findings, with clear clinical implications,
than when adopting qualitative or quantitative meth-
ods alone [26].
The limitations of our study are discussed. Firstly,
some may deliberate the capturing of self-efficacy by a
limited number of questions with fixed answering cat-
egories. However, we have chosen to make HSES a
feasible tool in daily clinical practice: quick, reliable
and valid. Secondly, the lack of patient report in con-
structing of the questionnaire is an omission as solely
expert opinion of haematologists, haemophilia nurses
and clinical psychologists was employed. Therefore,
patient interpretation of questions may differ. Thirdly,
due to practical reasons we were forced to exclude
patients with language difficulties due to the question-
naire-based nature of the study. We are thoroughly
aware, that specifically this group is characterized by
low self-efficacy and decreased adherence to medical
treatment [27]. Just as patients with inhibiting anti-
bodies against FVIII/FIX, may also be characterized
by low self-efficacy. We excluded this group, due to
the fact that their intensive treatment has such a
severe impact on daily life that it is not comparable to
standard prophylactic treatment. Exclusion of these
groups may have biased results towards underreport-
ing of low self-efficacy. However, despite exclusion of
these groups, HSES still differentiates between high
and low self-efficacy [28], proving the sensitivity of
the tool and its applicability in daily clinical practice.
Fourthly, we administered a parent-report asking how
Table 3. Convergent and divergent validity of the Haemophilia-specific
Self-efficacy Scale (HSES) with validation measures.
HSES total scale
Parent-report Adolescent-report
GSES* 0.43§ 0.81¶
Haemo-Qol†
Total score 0.45¶ 0.02
Physical 0.11 0.06
Feeling 0.32§ 0.36
View 0.38¶ 0.13
Family 0.27 0.25
Friends 0.09 0.34
Support 0.04 0.14
Others 0.30§ 0.55¶
Sport 0.30§ 0.02
Dealing 0.05 0.31
Treatment 0.13 0.48¶
Future 0.36 0.23
Relation 0.11 0.14
VERITAS-Pro‡
Total score 0.12 0.08
Time 0.10 0.13
Dose 0.11 0.16
Plan 0.28§ 0.03
Remember 0.29§ 0.22
Skip 0.26 0.12
Communicate 0.37¶ 0.14
*General self-efficacy scale.
†Haemophilia-specific health-related quality-of-life questionnaire.
‡Validated haemophilia regimen treatment adherence scale – prophylaxis.
§Spearman’s correlation coefficient is significant at the 0.05 level
(2-tailed).
¶Spearman’s correlation coefficient is significant at the 0.01 level
(2-tailed).
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parents perceive their own self-efficacy, but unfortu-
nately omitted how they perceive the self-efficacy of
their children, which would have been a valuable
addition. Furthermore, statistical analysis of sub-
groups was of course limited by small sample size. We
therefore recommend future studies to assess reliability
and validity in other subgroups of patients, and in
other settings and to utilize other qualitative research
methods such as cognitive debriefing.
Haemophilia-specific Self-Efficacy Scale properties
were satisfactory. A floor effect was absent as is fre-
quently the case in positively skewed assessments of
reported self-efficacy [21,29,30]. Skewing was
observed towards the most positive category (‘ceiling
effect’) as often reported in other surveys on self-effi-
cacy in chronic diseases [21,29,30]. This limitation
effects the discrimination between participants with a
high self-efficacy and restricts participants with a
high self-efficacy to acquire better scores in a follow-
up assessments. The ceiling effect can be explained
by several factors such as the extensive education of
patients and parents with regard to disease. In addi-
tion, current treatment focuses intensively on self-
management skills, patients and parents have been
dealing with the disease for a longer period of time,
and multiple family members may be affected, lead-
ing to more disease experience.
The HSES scale questionnaire’s internal consistency
was good. Cronbach’s alpha coefficients in similar
questionnaires were comparable [7,17,31]. The test–
retest reliability was adequate both in parents and
adolescents. The agreement between the perceived
haemophilia-specific self-efficacy of parents and ado-
lescents showed no correlation, as is often seen when
comparing parent-reported and adolescent-reported
outcomes on self-efficacy and quality-of-life question-
naires [32,33]. This is most likely explained by the dif-
ferences in treatment experience between parents and
adolescents as well as diverging management responsi-
bilities between parents and adolescents.
The convergent and divergent validity analyses of
HSES showed promising test results, which is of para-
mount importance to discriminate between optimal
and less optimal self-efficacy and to promote its future
use. Both parents and adolescents clearly expressed
similar opinions on their HSES report and their gen-
eral self-efficacy report. In addition, parents also
showed similar opinions on their disease-specific self-
efficacy as expressed by the HSES and quality-of-life
measurements by Haemo-QoL. However, the latter
was only observed in some subscales of the Haemo-
QoL in adolescents. Most probably, outcome is
influenced by growing and not yet complete responsi-
bility of adolescents for their disease, which directly
Table 4. Discrimination between validation measures between participants with low and high Haemophilia-specific Self-efficacy Scale(HSES) scores.
Validity measures
HSES total scale
Parent-report Adolescent-report
Low HSES score*
(n = 14); median [IQR]
High HSES score†
(n = 9); median [IQR] p-value‡
Low HSES score*
(n = 8); median [IQR]
High HSES score†
(n = 8); median [IQR] p-value‡
GSES, mean§ 32.50 [30.00–36.00] 38.00 [35.50–39.00] <0.01 30.00 [27.00–31.75] 39.50 [38.00–40.00] <0.01
Haemo-Qol¶
Total score 33.77 [25.97–42.59] 20.13 [6.25–24.91] <0.01 21.59 [16.75–33.33] 23.21 [20.45–24.59] 1.00
Physical 3.57 [0.00–25.89] 0.00 [0.00–8.93] 0.31 3.57 [0.00–25.89] 0.00 [0.00–26.79] 0.80
Feeling 10.94 [0.00–33.59] 0.00 [0.00–1.56] 0.02 4.69 [0.00–39.06] 0.00 [0.00–2.34] 0.13
View 20.14 [0.00–45.00] 0.00 [0.00–1.39] 0.01 8.75 [0.00–28.75] 3.75 [0.63–11.88] 0.72
Family 17.19 [6.25–33.59] 0.00 [0.00–25.00] 0.12 15.63 [0.00–35.16] 1.56 [0.00–14.06] 0.23
Friends 50.00 [25.00–70.31] 0.00 [0.00–84.38] 0.52 37.50 [0.00–65.63] 62.50 [34.38–95.31] 0.20
Support 53.13 [48.44–81.25] 100.00 [37.50–100.00] 0.25 75.00 [37.50–90.63] 81.25 [32.81–92.19] 0.73
Others 6.25 [0.00–30.21] 0.00 [0.00–2.08] 0.03 10.42 [0.00–78.13] 0.00 [0.00–0.00] 0.04
Sport 36.98 [6.25–62.50] 0.00 [0.00–5.56] <0.01 2.78 [0.00–20.83] 5.56 [0.00–11.11] 1.00
Dealing 41.07 [20.54–50.89] 42.86 [32.14–58.93] 0.37 42.86 [30.36–57.14] 51.79 [44.64–59.82] 0.28
Treatment 20.31 [9.38–32.81] 9.38 [0.00–34.38] 0.37 43.75 [22.66–75.00] 15.63 [7.03–33.59] 0.02
Future 34.38 [25.00–37.50] 21.88 [18.75–25.00] 0.07 37.50 [28.13–46.88] 21.88 [4.69–35.94] 0.13
Relation 0.00 [0.00–37.50] 0.00 [0.00–0.00] 0.57 0.00 [0.00–25.00] 0.00 [0.00–0.00] 0.83
VERITAS-Pro**
Total score 39.00 [29.75–43.00] 35.00 [29.00–38.50] 0.28 44.00 [40.50–54.75] 48.50 [39.25–55.25] 0.88
Time 5.50 [4.00–7.00] 5.00 [4.00–6.50] 0.48 6.50 [4.50–8.50] 6.00 [4.25–7.00] 0.72
Dose 4.50 [4.00–6.25] 4.00 [4.00–5.50] 0.48 4.50 [4.00–6.00] 5.00 [4.00–7.50] 0.72
Plan 8.00 [6.00–10.50] 4.00 [4.00–9.50] 0.10 10.50 [6.50–15.00] 9.00 [5.00–13.75] 0.80
Remember 8.00 [4.00–8.25] 4.00 [4.00–4.50] 0.05 5.00 [4.25–8.75] 7.00 [4.50–8.00] 0.72
Skip 5.00 [4.00–6.00] 4.00 [4.00–4.00] <0.01 5.00 [4.25–5.75] 4.50 [4.00–5.75] 0.50
Communicate 5.00 [4.00–6.25] 10.00 [6.00–11.50] 0.01 11.00 [7.50–16.00] 14.50 [8.50–16.00] 0.44
*Lowest 25% of HSES scores.
†Highest 25% of HSES scores.
‡Mann–Whitney U-test.
§General self-efficacy scale.
¶Haemophilia-specific quality-of-life questionnaire.
**Validated haemophilia regimen treatment adherence scale – prophylaxis.
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correlates with self-efficacy outcome and not with
quality-of-life outcome. Adequate transition towards
disease responsibility is of course expected of the adult
haemophilia patient. This development could be mea-
sured and monitored by HSES, making it an impor-
tant tool in the challenging transitional period
[7,34,35].
In line with our hypothesis, we found that adher-
ence to administered clotting factor concentrate doses
in relationship to prior prophylactic doses (subscales
‘Remember’ and ‘Skip’) was higher in parents with a
higher perceived haemophilia-specific self-efficacy. In
contrast, we found evidence that adherence to com-
munication with the HTC determined by the VERI-
TAS-Pro was significantly lower in parents with a
high perceived disease-specific self-efficacy than in par-
ents with a low perceived self-efficacy. Our hypothesis
is that the latter may be the consequence of the well-
developed self-management strategies of these parents,
decreasing communication moments. Further research
is necessary to objectify patient outcome in these
patients.
Conclusion
The HSES shows satisfactory psychometric properties
to describe the self-efficacy in paediatric haemophilia
patients on prophylactic home treatment. HSES par-
ent-report correlated with quality-of-life measures, fur-
ther underlining the importance to standardly assess,
monitor and improve self-efficacy. Validation in other
cohorts is impending to augment the value of HSES.
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